PPARβ/δ governs Wnt signaling and bone turnover

Nature Medicine

Volumn 19, Issue 5, 2013, Pages 608-613

  Scholtysek, Carina ^a,b   Katzenbeisser, Julia ^a   Fu, He ^c   Uderhardt, Stefan ^a,b   Ipseiz, Natacha ^a,b   Stoll, Cornelia ^a,b   Zaiss, Mario M ^a   Stock, Michael ^a,b   Donhauser, Laura ^a,b   Böhm, Christina ^a   Kleyer, Arnd ^a,b   Hess, Andreas ^a   Engelke, Klaus ^a   David, Jean Pierre ^a   Djouad, Farida ^d,e   Tuckermann, Jan Peter ^f,g   Desvergne, Béatrice ^c   Schett, Georg ^a   Krönke, Gerhard ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d INSERM   (France)

^e UNIV MONTPELLIER   (France)

^f FRITZ LIPMANN INSTITUTE   (Germany)

^g UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; BETA CATENIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; GENE ACTIVATION; GENE AMPLIFICATION; GENE EXPRESSION; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATOR GENE; WNT SIGNALING PATHWAY;

ALLELES; ANIMALS; BETA CATENIN; BONE AND BONES; BONE DISEASES, METABOLIC; BONE RESORPTION; FEMALE; GLUCOSE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; PPAR DELTA; PPAR-BETA; RANK LIGAND; TIME FACTORS; WNT PROTEINS; WNT SIGNALING PATHWAY;

MUS;

EID: 84877603089     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3146     Document Type: Article

References (35)

1. Evans, R.M., Barish, G.D. & Wang, Y.X. PPARs and the complex journey to obesity. Nat. Med. 10, 355-361 (2004).
2. Kawai, M. & Rosen, C.J. PPARγ: a circadian transcription factor in adipogenesis and osteogenesis. Nat. Rev. Endocrinol. 6, 629-636 (2010).
3. Giaginis, C., Tsantili-Kakoulidou, A. & Theocharis, S. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam. Clin. Pharmacol. 21, 231-244 (2007).
4. Viccica, G., Francucci, C.M. & Marcocci, C. The role of PPARγ for the osteoblastic differentiation. J. Endocrinol. Invest. 33, 9-12 (2010).
5. Grey, A. Skeletal consequences of thiazolidinedione therapy. Osteoporos. Int. 19, 129-137 (2008).
6. Akune, T. et al. PPARγ insuffciency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest. 113, 846-855 (2004).
7. Wan, Y., Chong, L.W. & Evans, R.M. PPAR-γ regulates osteoclastogenesis in mice. Nat. Med. 13, 1496-1503 (2007).
8. Wei, W. et al. PGC1β mediates PPARγ activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab. 11, 503-516 (2010).
9. Takada, I., Kouzmenko, A.P. & Kato, S. Wnt and PPARγ signaling in osteoblastogenesis and adipogenesis. Nat. Rev. Rheumatol. 5, 442-447 (2009).
10. Mulholland, DJ., Dedhar, S., Coetzee, G.A. & Nelson, C.C. Interaction of nuclear receptors with the Wnt/ß-catenin/Tcf signaling axis: Wnt you like to know? Endocr. Rev. 26, 898-915 (2005).
11. Takada, I., Suzawa, M., Matsumoto, K. & Kato, S. Suppression of PPAR transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts. Ann. NY Acad. Sci. 1116, 182-195 (2007).
12. Okamura, M. et al. COUP-TFII acts downstream of Wnt/ß-catenin signal to silence PPARygene expression and repress adipogenesis. Proc. Natl. Acad. Sci. USA 106, 5819-5824 (2009).
13. Kubota, T., Michigami, T. & Ozono, K. Wnt signaling in bone metabolism. J. Bone Miner. Metab. 27, 265-271 (2009).
14. Glass, D.A. II et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 8, 751-764 (2005).
15. Holmen, S.L. et al. Essential role of ß-catenin in postnatal bone acquisition. J. Biol. Chem. 280, 21162-21168 (2005).
16. Kramer, I. et al. Osteocyte Wnt/ß-catenin signaling is required for normal bone homeostasis. Mol. Cell Biol. 30, 3071-3085 (2010).
17. Wang, D., Mann, J.R. & DuBois, R.N. WNT and cyclooxygenase-2 cross-talk accelerates adenoma growth. Cell Cycle 3, 1512-1515 (2004).
18. Wang, D. et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor Ô. Cancer Cell 6, 285-295 (2004).
19. Nadra, K. et al. Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor ß/0. Mol. Cell Biol. 26, 3266-3281 (2006).
20. Hayashi, S., Lewis, P., Pevny, L. & McMahon, A.P. Effcient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Mech. Dev. 119, S97-S101 (2002).
21. Cui, Y. et al. Lrp5 functions in bone to regulate bone mass. Nat. Med. 17, 684-691 (2011).
22. Cho, E.S. et al. The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption. Mol. Cells 33, 173-181 (2012).
23. Chan, B.Y. et al. PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 40, 149-159 (2007).
24. Barish, G.D., Narkar, V.A. & Evans, R.M. PPARÔ: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 116, 590-597 (2006).
25. Narkar, V.A. et al. AMPK and PPARÔ agonists are exercise mimetics. Cell 134, 405-415 (2008).
26. Lee, N.K. et al. Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456-469 (2007).
27. Still, K., Grabowski, P., Mackie, I., Perry, M. & Bishop, N. The peroxisome proliferator activator receptor a/0 agonists linoleic acid and bezafbrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif. Tissue Int. 83, 285-292 (2008).
28. Olson, E.J., Pearce, G.L., Jones, N.P. & Sprecher, D.L. Lipid effects of peroxisome proliferator-activated receptor-0 agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb. Vasc. Biol. 32, 2289-2294 (2012).
29. Hayashi, S., Lewis, P., Pevny, L. & McMahon, A.P. Effcient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Gene expression patterns. Gene Expr. Patterns 2, 93-97 (2002).
30. Kleyer, A. et al. LXRs orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss. J. Bone Miner. Res. 27, 2442-2451 (2012).
31. Krönke, G. et al. R-spondin 1 protects against infammatory bone damage during murine arthritis by modulating the Wnt pathway. Arthritis Rheum. 62, 2303-2312 (2010).
32. Bouff, C., Bony, C., Courties, G., Jorgensen, C. & Noël, D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local infammation in experimental arthritis. PLoS ONE 5, e14247 (2010).
33. Dominici, M. et al. Minimal criteria for defning multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317 (2006).
34. Krönke, G. et al. Oxidized phospholipids induce expression of human heme oxygenase-1 involving activation of cAMP-responsive element-binding protein. J. Biol. Chem. 278, 51006-51014 (2003).
35. Pfaff, M.W. A new mathematical model for relative quantifcation in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).